Proposals for Next Classification Schema of Myeloid Neoplasms
Veterinary & Animal Sciences; Pioneer Valley Life
Health Informatics And Implementation Science
Rotations <p >Project 1: Genetic screens for proteins that modify or regulate the activity of microRNAs in C. elegans.
Postdoctoral positions are available for this lab. Please contact Junhao Mao directly, 508-856-4149 or via email, Junhao.Mao@umassmed.edu
<p >Rotation Projects: Characterization of gene which influences survival in sporadic ALS patients. Characterization of 2 newly identified familial ALS genes. Development of a new mouse model for familial ALS. Positional cloning of novel genes which cause familial ALS.
Donna M. and Robert J. Manning Chair in Neurosciences
Dr. Brown’s laboratory has focused on the identification of gene defects that elucidate the molecular pathogenesis of selected neuromuscular diseases including amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), muscular dystrophy, adrenoleukodystrophy, hereditary neuropathy and hyperkalemic periodic paralysis.
The lab is currently looking for motivated postdoctoral scholars with backgrounds in genomics and computational biology. Please email the PI.
Rotation projects are available related to malaria and Burkitt lymphoma. Our projects range from genetic epidemiology to directed genomics studying human, parasite and tumor.
A postdoc position is available to study in Dr. Ceol's lab.Click here to apply.
H. Arthur Smith Chair in Cancer Research
Rotation Projects Laboratory rotations are available to study signal mammalian transduction mechanisms. Several projects are available, including studies of protein kinase cascades, gene expression, the cell cycle, and apoptosis. Targeted gene disruption approaches in mice combined with biochemical and molecular biology studies will be examined.
Remondi Family Chair in Biomedical Research
POSTDOCTORAL POSITION: RNAI PRECLINICAL DEVELOPMENT Excellent training opportunity for a person considering industrial carrier in drug development Oligonucleotides represent a new class of drugs, which have the promise to become a major class of future therapeutics. There are several classes of oligonucleotides which can efficiently silence genes in various tissues with acceptable level of toxicity. There are also new chemistries being developed to further improve oligonucleotide tissue distribution and cellular uptake. The successful candidate will be a key part of an intra-disciplinary team working with biologists and chemists to develop novel types of therapeutics for treatment of neurological disease, liver disease and orphan indications. The work will include compounds identification, screening, characterization, in vivo efficacy and PK/PD studies, novel assays development etc. In addition exposure and training in nucleic acid pre-clinical development, project management etc will be provided. QUALIFICATIONS: Applicants must have (or expect to obtain shortly) a Ph.D. in Chemistry, Organic Chemistry Biochemistry, Cell Biology, Molecular Biology or a related field , be bright, ambitious, independent and collaborative and ideally, have research experience in nucleic acid molecular cell biology or pharmacology.
RNAI MEDICINAL CHEMISTRY/ RNA OLIGONUCLEOTIDE CHEMISTRY Develop and characterize novel RNA chemistries to promote efficient oligonucleotide internalization and tissue distribution. Oligonucleotides represent a new class of drugs, which have the promise to become a major class of future therapeutics. There are several chemistries and formulations developed by us and others that effectively support oligo internalization and favorable PK/PD. In most cases in vivo efficacy is limited by (1) poor PK (2) inefficient tissue distribution (3) compound entrapment in biologically inactive intracellular compartments. The objective of future studies will be development of novel chemistries, which promote receptor mediated cellular internalization and/ or endosomal escape. The successful candidate will be responsible for the design and synthesis of novel RNA precursors, optimization of RNA synthesis and conjugation protocols and interface with the biology part of the lab. In addition, exposure to pre-clinical development programs and oligonucleotide manufacturing will be available. QUALIFICATIONS: Applicants must have (or expect to obtain shortly) a Ph.D. in Chemistry, Organic Chemistry Biochemistry, Cell Biology, Molecular Biology or a related field , be bright, ambitious, independent and collaborative and have previous experience in nucleic acid / oligonucleotide chemistry.
SMALL RNA TRAFFICKING Discover, characterize and adapt mechanisms of small RNA extracellular and intracellular trafficking for development of novel classes of oligonucleotide drugs. A serious limitation in realizing the potential of oligonucleotide based therapies has been the exceedingly inefficient transit of oligonucleotides from outside cells to the intracellular compartments where the biologically relevant activity happens. On the other hand, there are multiple lines of evidence supporting the notion that nature has implemented evolutionarily conserved mechanisms and pathways for efficiently trafficking small RNAs across cellular boundaries. The objective of future studies will be the systematic evaluation of mechanisms of cellular uptake of different classes of oligonucleotides and their comparison to mechanisms of native RNA trafficking using a combination of experimental approaches, including advanced RNA chemistry and high temporal and spatial resolution microscopy in living cells, Mass spectrometry, cell biology and others. The successful candidate will work closely with Victor Ambros and Silvia Corvera labs and the UMASS imaging group and receive training in RNA chemistry, biochemistry, cell biology and pre-clinical development. QUALIFICATIONS:Applicants must have (or expect to obtain shortly) a Ph.D. in Chemistry, Organic Chemistry Biochemistry, Cell Biology, Molecular Biology or a related field , be bright, ambitious, independent and collaborative and ideally, have research experience in nucleic acid molecular and cell biology
Our laboratory uses a combination of nucleic acid and oligonucleotide chemistry, biochemistry, cell biology, and pharmacology and develops and evaluate novel technologies for development of oligonucleotide therapeutics. A rotation project is available to develop and identify chemically modified self-delivering RNAi compounds for treatment of Huntington and other diseases.
LAB ROTATION PROJECTS AVAILABLE -- PLEASE CONTACT SAM BEHAR FOR MORE INFORMATION
Focus: We seek to understand how the causative agent of tuberculosis, namely the bacterium Mycobacterium tuberculosis evades host immunity, and how different components of the immune response work together to contain infection. Our ultimate goal is to inform vaccine development and the design of host directed therapy.
Immediate opening! Two postdoctoral positions are available immediately to study cellular andmolecular mechanisms resulting in immunosuppression after alcohol use. Thefocus of this research is the role of monocytes and dendritic cells indecreased antigen-specific T cell activation after alcohol use.Intracellular signalling mechanisms resulting in decreased NF-kBactivation and inflammatory cytokine induction after acute alcoholconsumption are being investigated. Please contact Dr. Szabo for details.
A postdoctoral position is available to study in this laboratory. Contact Dr. Rogaev for additional details.
Gretchen Stone Cook Chair in Biomedical Sciences
A postdoctoral position is available to study in this laboratory. Contact Dr. Zamore for additional details
Potential Rotation Projects Our laboratory uses a combination of biochemistry, cell biology, and genetics to dissect the RNAi pathway. A rotation project is available to explore the mechanisms that underlie the RNAi phenomenon or the biological pathways in which RNAi enzymes participate in flies, mice and humans.
Rotation Projects <p >We have identified a number of bacterial pathways that are required for bacterial viability or virulence. We are particularly interested in: Phosphosignaling systems that regulate cell wall synthesis Metabolic regulatory mechanisms that trigger the “dormancy” response observed during infection. <p >A variety of genetic, biochemical, and informatic methods will be used to define the functions of these genes and the role played by each during infection. <p >
<p >Rotation Projects <p >Rotation projects are designed to expose students to the molecular cell biology of solid tumors and to provide them with an appreciation for translational cancer research. Specific rotation projects, which are focused on the major themes of the lab, include: <p >Function and Regulation of Integrins (Cell Adhesion Receptors) in Cancer Epigenetic mechanisms that regulate integrin gene expression in human cancers Regulation of integrin expression and function during the EMT Role of specfic microRNAs (miRs) in regulating integrin function and signaling Contribution of integrins to carcinoma progression using mouse models of breast carcinoma <p >Vascular Endothelial Growth Factor (VEGF) Signaling, EMT and Carcinoma Progression Function and expression of VEGF receptors in carcinoma cells Regulation of VEGF transcription in response to EMT stimuli Role of miRs in regulating VEGF receptors and signaling Contribution of VEGF signaling to the behavior of aggressive, de-differentiated carcinomas <p >Nuclear Hormone Receptors and EMT Role of estrogen receptors in regulating the EMT Regulation of VEGF transcription by estrogen receptors
Rotation projects are designed to expose students to the biology of adult stem cells, the mechanisms of tumorigenesis and to provide them with an appreciation for translational cancer research. These projects are focused on the major themes of the lab, which are: 1. Understanding the relative effects of oncogenic mutations on stem cells compared to the non-stem cell population from adult human skin. A key component of this project is to evaluate the Beta-catenin/Lef-1 signaling pathway on cultured epithelial stem cells and non-stem cells. 2. Studying the function of differently expressed genes in mediating stem cell behavior. The goal of this project is to understand the molecular mechanisms which control the critical properties of stem cell self-renewal, proliferation, adhesion and migration. 3. Identifying, isolating and characterizing “cancer stem cells” from human and mouse model tumors. Cancers are thought to possess a sub-population of slowly-cycling cancer stem cells which are responsible for tumor growth, recurrence and metastasis. The goal of this project is to begin to characterize these cells to help better target them therapeutically. The goal for all of these projects is to use the data obtained to help understand human tumorigenesis at the molecular, cellular and tissue levels, and be able to devise better treatments.
Richard M. Haidack Professor in Medicine
Population and Quantitative Health Sciences
Tweets by @DrSherryPagoto
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Joseph D. Early Chair in Biomedical Research
Prevention Strategies for Second Primary Malignancies After CAR-T Therapy
The Darkest Side of AML: The TP53 Mutation
Clonal Hematopoiesis in Clinical Practice: Real-World Insights
Unpacking CHIP: Recent Updates, Remaining Questions
Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCT
Effects of donor-engrafted clonal hematopoiesis in stem cell transplantation
High-Risk Myelodysplastic Syndrome Findings in the SELECT-MDS-1 Study
Stem Cell Transplantation: How Clonal Hematopoiesis Shapes Patient Outcomes
Olutasidenib as a Breakthrough for R/R mIDH1 AML Patients
The Impact of Mutations in Clonal Hematopoiesis
TP53 in MDS & AML Prognostication & Treatment Strategies
Exploring the Biological Basis of TP53-Aberrant MDS & AML
Improving Outcomes in Blast Phase Chronic Myeloid Leukemia
ASH Clinical News - Practical Solutions Amid Cuts to Federally Funded Research
OncLive with Dr. Patel and Dr. Gerber: p53 Immunohistochemistry
Early Identification of TP53-Mutant MDS and AML Using p53 Immunostaining
Point-of-Care p53 IHC Unveils TP53-Mutant MDS/AML
IHC Enables Rapid Identification of TP53-Mutant MDS/AML
ASH Clinical News: p53 Immunohistochemistry for TP53-Mutant MDS/AML
p53 Immunostain in TP53-Mutant MDS and AML